<code id='EB6EF0DE3D'></code><style id='EB6EF0DE3D'></style>
    • <acronym id='EB6EF0DE3D'></acronym>
      <center id='EB6EF0DE3D'><center id='EB6EF0DE3D'><tfoot id='EB6EF0DE3D'></tfoot></center><abbr id='EB6EF0DE3D'><dir id='EB6EF0DE3D'><tfoot id='EB6EF0DE3D'></tfoot><noframes id='EB6EF0DE3D'>

    • <optgroup id='EB6EF0DE3D'><strike id='EB6EF0DE3D'><sup id='EB6EF0DE3D'></sup></strike><code id='EB6EF0DE3D'></code></optgroup>
        1. <b id='EB6EF0DE3D'><label id='EB6EF0DE3D'><select id='EB6EF0DE3D'><dt id='EB6EF0DE3D'><span id='EB6EF0DE3D'></span></dt></select></label></b><u id='EB6EF0DE3D'></u>
          <i id='EB6EF0DE3D'><strike id='EB6EF0DE3D'><tt id='EB6EF0DE3D'><pre id='EB6EF0DE3D'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:focus    Page View:78281

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In